Cargando…
D2‐resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy
Although adjuvant chemoradiotherapy has been an important part in the treatment of gastric cancer, whether or not adjuvant radiation can benefit patients undergoing resection with D2 lymph node dissection remains controversial. This retrospective study aimed to evaluate the role of adjuvant chemorad...
Autores principales: | Peng, Jin, Wei, Yuehua, Zhou, Fuxiang, Dai, Jing, Zhong, Yahua, Xie, Conghua, Qin, Yue'e, Gong, Jun, Xiong, Bin, Zhou, Yunfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083730/ https://www.ncbi.nlm.nih.gov/pubmed/27666138 http://dx.doi.org/10.1002/cam4.873 |
Ejemplares similares
-
Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer
por: Voutsadakis, Ioannis A.
Publicado: (2016) -
Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer
por: Che, Keying, et al.
Publicado: (2020) -
Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2019) -
Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer
por: Ma, Gui-Fen, et al.
Publicado: (2019) -
Improving survival of stage II‐III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy
por: Li, Yang, et al.
Publicado: (2020)